Evidence map›Paper›PMID 32990921›Full record

SynthesisAdvances in therapy2020

Evaluation of Patients with Insufficient Efficacy and/or Tolerability to Triptans for the Acute Treatment of Migraine: A Systematic Literature Review.

Elizabeth Leroux, Andrew Buchanan, Louise Lombard, Li Shen Loo, Daisy Bridge, Ben Rousseau, Natasha Hopwood, Brandy R Matthews, Uwe Reuter

Open access · hybridAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Advances in therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 5 pooled it
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 5 syntheses or guidelines pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Review
  16. Acute treatment of migraine: quantifying the unmet need through real-world data in Italy.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Elizabeth LerouxBrunswick Medical Center, Montréal, QC, Canada.
Andrew BuchananEli Lilly and Company, Indianapolis, IN, USA. buchanan_andrew_s@lilly.com.ORCID http://orcid.org/0000-0002-8361-482X
Louise LombardEli Lilly and Company, Indianapolis, IN, USA.
Li Shen LooEli Lilly and Company, Indianapolis, IN, USA.
Daisy BridgeAdelphi Values, Bollington, Cheshire, UK.
Ben RousseauAdelphi Values, Bollington, Cheshire, UK.
Natasha HopwoodAdelphi Values, Bollington, Cheshire, UK.
Brandy R MatthewsEli Lilly and Company, Indianapolis, IN, USA.
Uwe ReuterDepartment of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany.
Eli Lilly (United States) · USAdelphi Group (United Kingdom) · GBCharité - Universitätsmedizin Berlin · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionUse of triptans for acute treatment of migraine is associated with insufficient efficacy and/or tolerability in approximately 30-40% of people. We conducted a systematic literature review (SLR) to synthesize definitions, terminology, subsequent treatment outcomes, and characteristics associated with this subpopulation.

methodsA comprehensive SLR was conducted to identify studies, published from Jan 1995 to May 2019, which focused on insufficient efficacy and/or tolerability to triptans.

resultsThirty-five publications were identified, of which 22 described randomized controlled trials and open-label studies, and 13 described observational studies. Across studies, multiple objectives and a high amount of variability in methodologies and outcomes were noted. The most commonly applied measures of efficacy were headache pain freedom and pain relief at 2 h. Ten studies assessed efficacy of switching or optimizing treatment in patients with historical insufficient efficacy or tolerability to previous triptan treatment and demonstrated varying levels of success. Factors associated with increased risk of triptan insufficient efficacy included severe baseline headache severity, photophobia, phonophobia, nausea, and depression.

conclusionsIrrespective of the methodology or definition used to identify people with insufficient efficacy and/or tolerability to triptans, study results support the assertion that a high unmet need remains for effective acute treatment of migraine.

Indexed as

Administration, OralAdultFemaleHumansMaleMiddle AgedMigraine DisordersNauseaPain ManagementRandomized Controlled Trials as TopicSerotonin Receptor AgonistsSeverity of Illness IndexTreatment OutcomeTryptaminesSerotonin Receptor AgonistsTryptaminesAcute treatmentInsufficient efficacy and/or tolerability to triptansMigraineTriptan non-respondersTriptan responseTriptans

Identifiers

PMID32990921
PMCPMC7595976
OpenAlexW3091008395

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.